Here are 1-3 brief analogies for Candel Therapeutics (CADL):

• Moderna for cancer immunotherapies.
• A clinical-stage biotech aiming to be the next Vertex Pharmaceuticals, but solely focused on developing novel cancer immunotherapies.

Candel Therapeutics' major product candidates are:

• CAN-2409: An immunotherapy being developed for the treatment of pancreatic, prostate, lung cancer, and high-grade glioma.
• CAN-3110: An immunotherapy in early-stage clinical trials for the treatment of recurrent glioblastoma.

Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on the development of immunotherapies for cancer patients. As such, its product candidates (CAN-2409 and CAN-3110) are currently in various stages of clinical trials (Phase I, II, and III).

At this stage of development, Candel Therapeutics does not have major customers in the traditional sense of selling approved products or services to other companies or individuals. The company's primary activities involve research, development, and conducting clinical trials to gather data for regulatory approval. Revenues for such companies typically come from equity financing, grants, or potential collaboration agreements, rather than product sales to customers.

Rentschler Biopharma SE

Lonza Group AG (LONN.SW)

Paul Peter Tak, M.D., Ph.D., FMedSci President & Chief Executive Officer Dr. Paul Peter Tak has served as President and Chief Executive Officer of Candel Therapeutics and as a board member since September 2020, during which he oversaw the company's IPO process on Nasdaq in 2021. He previously held the position of President and CEO of Tempero Pharmaceuticals, which was later acquired by GlaxoSmithKline (GSK). From 2018 to 2020, Dr. Tak was a venture partner at Flagship Pioneering and also served as President and CEO of Kintai Therapeutics, a company that subsequently merged with Senda Biosciences. His extensive career includes serving as Senior Vice President, Chief Immunology Officer, and Global Development Leader at GSK from 2011 to 2018. He has also been a board director for Galvani Bioelectronics, ViiV Healthcare, and Omega Therapeutics and currently serves on the Board of Sitryx Therapeutics (which he co-founded) and Levicept, in addition to being the Chair of the Board of Citryll. Charles Schoch Chief Financial Officer Charles Schoch was appointed permanent Chief Financial Officer of Candel Therapeutics effective June 23, 2025, after serving as interim CFO since January 2024. He joined Candel in November 2021, holding various financial reporting and accounting roles, including VP of Finance and Corporate Controller. As interim CFO, he played a crucial role in leading a capital raise that generated approximately $86 million in net proceeds for the company following positive Phase 3 clinical trial results. Prior to joining Candel, Mr. Schoch was the Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. He also spent seven years at PwC's Health Industry assurance practice, where he audited a diverse range of life sciences clients, including pre-IPO and multinational public companies. Earlier in his career, he worked as a financial and operational consultant for several Third Rock Venture portfolio companies, indicating experience with companies backed by private equity firms. Francesca Barone, M.D., Ph.D. Chief Scientific Officer Dr. Francesca Barone oversees the research and development of Candel Therapeutics' proprietary enLIGHTEN™ Discovery Platform. W. Garrett Nichols, M.D., M.S. Chief Medical Officer Dr. W. Garrett Nichols was named Chief Medical Officer of Candel Therapeutics on September 7, 2022. He brings extensive biopharmaceutical experience to the company. Seshu Tyagarajan, Ph.D., RAC Chief Technical and Development Officer Dr. Seshu Tyagarajan is a member of Candel Therapeutics' leadership team.

Candel Therapeutics (CADL), as a clinical-stage biopharmaceutical company, faces inherent risks primarily related to the development and commercialization of its product candidates.

Key Risks to the Business

1. Clinical Trial and Regulatory Risk: The primary risk to Candel Therapeutics stems from the uncertainty of successfully completing clinical trials and obtaining regulatory approvals for its drug candidates. The company's lead candidates, CAN-2409 and CAN-3110, are in various stages of clinical development, including Phase II and Phase III trials. Despite positive interim or topline data, the success rate for drugs advancing from clinical trials to market approval is low, typically less than 12%. Even if clinical trials demonstrate efficacy and safety, there is no guarantee of FDA approval, and the regulatory process itself is complex and lengthy. Furthermore, even with approval, there remains a risk related to the effective execution of the commercial launch and market acceptance of these novel oncolytic viral immunotherapies.
2. Financial Risk and Capital Dependence: As a clinical-stage company, Candel Therapeutics currently generates no revenue and operates at a net loss, relying heavily on external funding to finance its research and development activities and other operations. While the company has secured financing, including a term loan facility, to extend its cash runway, it continues to incur significant operating losses driven by rising R&D expenses. Future capital raises may be necessary, and there is a risk that such funding may not be available on favorable terms, or at all. Additionally, restrictive covenants in debt agreements could limit the company's financial and operational flexibility and increase the risk of default.
3. Market Acceptance and Commercialization Risk: Even upon successful regulatory approval, Candel Therapeutics' products face the risk of not achieving significant market acceptance or generating substantial sales. The biopharmaceutical market is highly competitive, and Candel's viral-based immunotherapy approach may face skepticism or challenges in widespread adoption by healthcare providers and patients. For instance, while CAN-2409 has shown promising results in prostate cancer, questions remain regarding its differentiation and value proposition given existing treatment options. Pricing pressures and the need to demonstrate compelling value to justify the cost of novel therapies also pose significant commercialization challenges.

null

Candel Therapeutics (symbol: CADL) focuses on developing immunotherapies for various cancers. The addressable markets for its main product candidates are outlined below:

Product/Service	Disease	Addressable Market Size	Region
CAN-2409	Pancreatic Cancer	USD 3.25 billion (in 2025)	Global
CAN-2409	Prostate Cancer	USD 17.0 billion (in 2024)	Global
CAN-2409	Lung Cancer	USD 35.1 billion (in 2024)	Global
CAN-2409	High-Grade Glioma	~USD 830 million (in 2023)	7 Major Markets (US, EU4, UK, Japan)
CAN-3110	Recurrent Glioblastoma	USD 380.6 million (in 2025)	Global

Candel Therapeutics (CADL), a clinical-stage biopharmaceutical company, is expected to drive its future revenue growth over the next 2-3 years through the following key initiatives:

1. Commercialization of CAN-2409 in Localized Prostate Cancer: The primary driver of future revenue growth is the anticipated commercial launch of CAN-2409 for the treatment of localized prostate cancer. Candel Therapeutics plans to submit a Biologics License Application (BLA) for CAN-2409 in this indication in the fourth quarter of 2026. If approved, this would mark the company's first commercial product, with analysts forecasting the commencement of revenue generation in 2027, significantly increasing in 2028.

2. Advancement of CAN-2409 in Non-Small Cell Lung Cancer (NSCLC): The initiation of a pivotal Phase 3 clinical trial for CAN-2409 in metastatic non-squamous non-small cell lung cancer (NSCLC) is expected in the second quarter of 2026. Positive outcomes from this late-stage trial would significantly expand the potential market for CAN-2409, increasing the asset's value and laying the groundwork for substantial future revenue growth, potentially through commercialization or strategic partnerships beyond the immediate 2-3 year horizon.

3. Strategic Collaborations and Licensing Agreements: As Candel Therapeutics progresses its lead therapeutic candidates through clinical development and toward potential commercialization, positive clinical data, particularly for CAN-2409, could lead to further strategic collaborations or out-licensing agreements. Such partnerships could generate upfront payments, milestone payments, or royalty streams, contributing to the company's revenue. Candel has already established a royalty funding agreement tied to the FDA approval of CAN-2409 in prostate cancer and a commercial collaboration for strategic input.

Share Issuance

• Candel Therapeutics completed its Initial Public Offering (IPO) in July 2021, raising $79.1 million by offering 9,000,000 shares of common stock.
• In December 2024, the company closed an underwritten public offering, generating approximately $92 million in gross proceeds from the sale of common stock and pre-funded warrants.
• Candel Therapeutics completed a follow-on equity offering in February 2026, raising approximately $100 million in gross proceeds from the issuance of 18,348,624 common shares at $5.45 per share.

Inbound Investments

• In October 2025, Candel Therapeutics secured a five-year, $130 million term loan facility with Trinity Capital Inc., with an initial $50 million drawn at closing.
• In February 2026, Candel announced a $100 million royalty funding agreement with RTW Investments, LP, contingent on FDA approval of aglatimagene in localized prostate cancer.
• As of April 2025, institutional investors held approximately 41.99% of Candel Therapeutics' shares, reflecting significant external investment in the company's equity.

Capital Expenditures

• Candel Therapeutics invested $16K in capital expenditures during fiscal year 2024.
• For Q3 2025, capital expenditures amounted to $144K.